Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in ...

25 October 2026 · By · Wire by Fusion42

Published

25 October 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at businesswire.com →

◆ Verified

Fusion42 · 25 October 2026 · Fusion42 review

Xencor announced Phase 1 dose selection data for XmAb819, a first-in-class ENPP3 x CD3 bispecific T-cell engager for advanced clear cell renal cell carcinoma (ccRCC). The chosen recommended Phase 3 dose is 400 mcg/kg showing promising response rates, with plans for accelerated FDA approval discussions and a global randomized Phase 3 study by end of 2027.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You are seeing a solid clinical validation in a tough renal cancer case with a new immune therapy mechanism. This opens a path for earlier use and combination trials if you work on targeted cancer therapies.

◆ Coverage

1 source · 25 Oct 2026

◆ Related on Wire

◆ Topics

Biotechbiotechoncologydrug-developmentclinical-trialsrenal-cell-carcinomabispecific-antibody